N Tomita1, K Okuda2, S Osaga3, A Miyakawa4, R Nakanishi2, Y Shibamoto5. 1. Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. c051728@yahoo.co.jp. 2. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 3. Clinical Research Management Center, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 4. Department of Radiation Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. 5. Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Abstract
PURPOSE: To investigate whether surgery and stereotactic body radiotherapy (SBRT) yield comparable outcomes for clinical stage (c-stage) I non-small-cell lung cancer (NSCLC), propensity score-matching (PSM) analysis was conducted. METHODS: This single-institutional retrospective study included patients who underwent surgery (n = 574) or SBRT (n = 182) between 2004 and 2014. PSM was performed based on tumor diameter, age, sex, performance status, forced expiratory volume, Charlson comorbidity index, and ground glass nodules (GGN) defined as cTis or cT1mi according to the 8th TNM classification. RESULTS: The median follow-up durations for the surgery and SBRT groups were 66 and 69 months, respectively. The multivariate analysis revealed that non-GGN was a significant factor for poorer overall survival (OS) and disease-free survival (DFS): hazard ratio (HR) 19.95% confidence interval (CI) 4.7-79, P < 0.001; and HR 28, 95% CI 6.9-110, P < 0.001, respectively. PSM identified 120 patients from each group. The 5-year OS and DFS rates of the surgery vs SBRT groups were 71% (95% CI 61-79) vs 64% (95% CI 54-72) (P = 0.41) and 63% (95% CI 53-72) vs 55% (95% CI 45-63) (P = 0.23) after PSM, respectively. CONCLUSION: The PSM analyses including the ratio of GGN demonstrated that the OS and DFS for patients with c-stage I NSCLC in the surgery group were slightly superior to those for those in the SBRT group, although both survivals were not significantly different between the two therapeutic approaches.
PURPOSE: To investigate whether surgery and stereotactic body radiotherapy (SBRT) yield comparable outcomes for clinical stage (c-stage) I non-small-cell lung cancer (NSCLC), propensity score-matching (PSM) analysis was conducted. METHODS: This single-institutional retrospective study included patients who underwent surgery (n = 574) or SBRT (n = 182) between 2004 and 2014. PSM was performed based on tumor diameter, age, sex, performance status, forced expiratory volume, Charlson comorbidity index, and ground glass nodules (GGN) defined as cTis or cT1mi according to the 8th TNM classification. RESULTS: The median follow-up durations for the surgery and SBRT groups were 66 and 69 months, respectively. The multivariate analysis revealed that non-GGN was a significant factor for poorer overall survival (OS) and disease-free survival (DFS): hazard ratio (HR) 19.95% confidence interval (CI) 4.7-79, P < 0.001; and HR 28, 95% CI 6.9-110, P < 0.001, respectively. PSM identified 120 patients from each group. The 5-year OS and DFS rates of the surgery vs SBRT groups were 71% (95% CI 61-79) vs 64% (95% CI 54-72) (P = 0.41) and 63% (95% CI 53-72) vs 55% (95% CI 45-63) (P = 0.23) after PSM, respectively. CONCLUSION: The PSM analyses including the ratio of GGN demonstrated that the OS and DFS for patients with c-stage I NSCLC in the surgery group were slightly superior to those for those in the SBRT group, although both survivals were not significantly different between the two therapeutic approaches.
Entities:
Keywords:
Matched-pair analysis; Non-small-cell lung cancer; Outcome; SBRT; Thoracic surgery
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Frank J Lagerwaard; Naomi E Verstegen; Cornelis J A Haasbeek; Ben J Slotman; Marinus A Paul; Egbert F Smit; Suresh Senan Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: Mojgan Taremi; Andrew Hope; Max Dahele; Shannon Pearson; Sharon Fung; Thomas Purdie; Anthony Brade; John Cho; Alexander Sun; Jean-Pierre Bissonnette; Andrea Bezjak Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-04 Impact factor: 7.038
Authors: Traves D Crabtree; Chadrick E Denlinger; Bryan F Meyers; Issam El Naqa; Jennifer Zoole; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Jeffrey D Bradley Journal: J Thorac Cardiovasc Surg Date: 2010-04-18 Impact factor: 5.209
Authors: David Palma; Otto Visser; Frank J Lagerwaard; Jose Belderbos; Ben Slotman; Suresh Senan Journal: Radiother Oncol Date: 2011-07-19 Impact factor: 6.280
Authors: N E Verstegen; J W A Oosterhuis; D A Palma; G Rodrigues; F J Lagerwaard; A van der Elst; R Mollema; W F van Tets; A Warner; J J A Joosten; M I Amir; C J A Haasbeek; E F Smit; B J Slotman; S Senan Journal: Ann Oncol Date: 2013-02-20 Impact factor: 32.976
Authors: John Varlotto; Achilles Fakiris; John Flickinger; Laura Medford-Davis; Adam Liss; Julia Shelkey; Chandra Belani; Jill DeLuca; Abram Recht; Neelabh Maheshwari; Robert Barriger; Nengliang Yao; Malcolm DeCamp Journal: Cancer Date: 2013-04-19 Impact factor: 6.860
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005